$13.37
-1.39 (-9.42%)
Open$14.27
Previous Close$14.76
Day High$14.99
Day Low$13.37
52W High$2.42
52W Low$0.32
Volume—
Avg Volume526.0K
Market Cap17.01M
P/E Ratio—
EPS$-1.58
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+203.0% upside
Current
$13.37
$13.37
Target
$40.51
$40.51
$28.40
$40.51 avg
$50.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 6.30M | 6.48M | 4.92M |
| Net Income | -1,316,650 | -1,573,823 | -1,131,717 |
| Profit Margin | -20.9% | -24.3% | -23.0% |
| EBITDA | -2,363,922 | -2,326,744 | -1,866,701 |
| Free Cash Flow | -1,722,588 | -1,580,767 | -1,263,847 |
| Rev Growth | -2.8% | +6.4% | +0.2% |
| Debt/Equity | 0.17 | 0.14 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |